ABLC lipid formulation of amphotericin B data

LIPO will present posters at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) on Oct. 7, showing efficacy of the agent in fusariosis and in aspergillosis.

Of 183 patients who had failed treatment with the free form of the drug or other systemic antifungals, 69 percent responded to ABLC. Patients who had suffered kidney toxicity from the free form showed statistically significant improvement in kidney function when treated with ABLC, the company announced at an analyst meeting held at LIPO's headquarters in Princeton, N.J. ...